Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesPharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes
Diabetic Medicine, 11/09/09
Kapitza C et al. – Plasma concentrations peaked within 24 h after injection and were sustained for >= 14 days with all doses. In comparison with placebo, the 8– and 30–mg doses of taspoglutide significantly reduced glycaemic parameters, including 24–h blood glucose and 5–h postprandial glucose areas under the curve (AUCs), for up to 14 days with the 30–mg dose. The most common adverse events, primarily gastrointestinal in nature, were dose–dependent and transient. A single dose of taspoglutide significantly improved glycaemic parameters in Type 2 diabetes patients for up to 14 days. The formulation was well tolerated and appears suitable for weekly administration.
Related Articles
Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Relevance Score: 90%
Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Metabolism-Clinical and Experimental, 11/03/09
Relevance Score: 90%
A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus
Pharmacotherapy, 10/28/09
Relevance Score: 90%
Hepatic fat and inflammation in type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 90%
Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study
International Journal of Obesity, 10/16/09
Relevance Score: 90%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Zoledronic acid: an unending tale for an antiresorptive agent
Expert Opinion in Pharmacotherapy, 12/11/09
Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease
Expert Opinion in Pharmacotherapy, 12/11/09
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Today in Endocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease
Expert Opinion in Pharmacotherapy, 12/11/09
Obesity in older adults: relationship to functional limitation
Current Opinion in Clinical Nutrition & Metabolic Care, 12/11/09
Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment
Medical Principles and Practice, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor